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The influence of statin exposure on inflammatory
markers in patients with early bacterial infection:
pilot prospective cohort study
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and Neill KJ Adhikari8
Abstract
Background: In the context of infection, progressive illness resulting in acute organ dysfunction is thought to be
secondary to inflammatory response. Our aims were to determine risk factors for progressive illness following
infection in a low-risk hospitalised cohort, including the impact of prior stain therapy.
Methods: We performed a prospective observational cohort study on two adult acute medical wards of a single
tertiary academic hospital. We screened drug prescription charts of all adult acute medical admissions for inclusion
criteria of inpatient administration of antibiotics for more than 24 hours for a microbiologically confirmed or
clinically suspected infection. Patients were followed until admission to a high dependency unit (HDU) or intensive
care unit (ICU), discharge from hospital, or to a maximum of 10 days. Outcomes were evolution of systemic
inflammatory response syndrome (SIRS) criteria, white cell count and C-reactive protein measurements, and adverse
clinical outcomes. We constructed multivariable models accounting for repeated within-patient measurements to
determine associations between a priori selected predictors (days since admission, age, gender, Charlson score, prior
statin exposure) and selected outcomes.
Results: We enrolled 209 patients; 27.8% were statin users and the commonest infection was pneumonia (51.0%).
Most (88.0%) had at least 1 SIRS criterion on admission, and 76 (37.3%) manifested additional SIRS criteria over time.
Risks of admission to HDU/ICU (3.3%) and of 30-day mortality (5.7%) were low. The proportion of patients with at
least 1 SIRS criterion, mean CRP, and mean WBC all decreased over time. Multivariable regression models identified
days since hospital admission as the only variable associated with daily presence of SIRS criteria, WCC, or CRP
(adjusted OR <1 and p < 0.0001 in all analyses). Statin exposure was not a significant predictor.
Conclusions: This cohort of ward patients treated for infection had a low risk of clinical deterioration, inflammatory
markers improved over time, and statin exposure was not associated with any outcome. Future larger studies may
identify risk factors for progression of illness in this population and plausible surrogate endpoints for evaluation in
clinical trials.
Keywords: Sepsis, Biomarkers, Surrogate end-points, Progression of illness
* Correspondence: marius.terblanche@kcl.ac.uk
7Centre for Critical Illness Data Sciences Research, Division of Health & Social
Care Research, King’s College London, Department of Critical Care Medicine,
1st Floor, East Wing, St. Thomas’ Hospital, Westminster Bridge Road, London
SE1 7EH, UK
Full list of author information is available at the end of the article
© 2014 Shankar-Hari et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Shankar-Hari et al. BMC Anesthesiology 2014, 14:106
http://www.biomedcentral.com/1471-2253/14/106
Background
Systemic inflammatory response in the presence of
infection defines sepsis [1]. Patients admitted acutely to
hospital with infections are at risk of developing a pro-
gressive host inflammatory response leading to organ
dysfunction [2-4], a group of heterogeneous syndromes
defined as severe sepsis [1]. Patients managed in an in-
tensive care unit (ICU) with sepsis are also at risk devel-
oping a progressive illness trajectory associated with
adverse outcomes [3,5,6]. The ICU-treated population
incidence of sepsis is substantial (1 ± 0.5 cases per 1000)
[7]. Given this risk of organ dysfunction [8,9], the repor-
ted minimal treatment effects and potential for harm
with interventions for established organ failure [10,11],
an alternative approach is to evaluate drugs with pleo-
tropic effects to prevent progressive organ dysfunction
in a pre-ICU population of patients with infection.
One candidate drug class to prevent organ dysfunction
in at-risk patients are statins, for which biological plausi-
bility and proof of concept data exist for salutary effects
on infection-related inflammatory response [12,13]. How-
ever, to design a randomized controlled trial (RCT) of any
intervention to prevent organ dysfunction in patients with
acute infection, it is crucial to understand the incidence,
timing, and risk factors for acute organ dysfunction [14].
We therefore conducted a prospective cohort study of
patients hospitalised with infection to determine the
evolution of clinical and laboratory criteria for the sys-
temic inflammatory response syndrome (SIRS) variables,
and secondarily, the impact of prior statin therapy on this
outcome.
Methods
Study design and setting
We performed a prospective observational cohort study
on two adult acute medical wards of a single tertiary
academic hospital, to which non-surgical patients with
infections are routinely admitted. These patients are re-
viewed twice daily in post-take rounds led by a senior
clinician. The use of antibiotics, including selection, start
time, and duration is managed by the treating team with
input from pharmacists and daily microbiology rounds.
The study was approved by the Research Ethics Commit-
tee of Guy’s & St Thomas’ NHS Foundation Trust. Given
that only anonymised data extracted from clinical records
were used, the Research Ethics Committee waived the
need for informed consent.
Participants
We screened the drug prescription chart of all patients ad-
mitted between April and September 2008 and selected pa-
tients >16 years old with a working or confirmed diagnosis
of infection, defined by administration of antibiotics for
more than 24 hours since admission for a microbiologically
confirmed or clinically suspected infection. We excluded
those who had received prophylactic antibiotics; antibiotics
received for less than 24 hours; and direct admissions to a
high dependency unit (HDU) or ICU.
Data collection and follow-up
All study variables were obtained from paper medical re-
cords and the hospital’s clinical information system. For
all enrolled patients we prospectively collected baseline
data, including demographics, co-morbidities (using the
Charlson Index [15]), chronic medications including
prior statin therapy, and details of current illness (type
of infection, severity of illness). To determine statin ex-
posure, we used information obtained from clinical re-
cords to determine whether a patient took a statin for
most days of the 4 weeks before admission. Accurate
medication history is routinely collected by ward-based
pharmacists who participate in post-admission ward
rounds, and used by the clinical team to ensure appro-
priate continuation of chronic medications in hospital.
Patients are asked directly about their medication his-
tory, but when they are unable to provide details, the
next of kin or general medical practitioner is contacted.
For the first 10 days of admission, we also collected
physiological variables (systolic and diastolic blood pressure,
heart and respiratory rates, temperature, oxygen saturation
and neurological status), inflammation-related laboratory
findings (white cell counts [WCC], and C-reactive protein
[CRP]), and treatments received (oxygen supplementation,
intravenous fluids, enteral nutrition, statins, other drugs).
The blood tests described were not part of a study protocol
and results were only available if these were collected as
part of usual patient care. Follow-up continued until ad-
mission to HDU/ICU, discharge from hospital, or to a
maximum of 10 days (including the day of admission),
whichever came first. We also searched the hospital’s elec-
tronic patient record (EPR) to determine the patient’s vital
status and location 30 days after admission (hospital ward;
ICU/HDU; discharged from hospital). We recorded data
related to re-admission to our hospital, if applicable.
Research assistants abstracted and recorded data on
study forms, and two investigators (AD and MT) entered
data into the study database (Microsoft© Access 2003,
Microsoft Corporation, Seattle, USA), with each checking
a random sample of data entered by the other for tran-
scription errors. To further improve data integrity, the
study database was programmed to reject out-of-range
values, and an investigator (MT) checked a random sam-
ple of data recorded on study forms (approximately 10%
of values or patients).
Outcomes
Our primary outcome measures were the changes in the
systemic inflammatory response syndrome (SIRS) during
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the follow-up period, defined as the proportion of pa-
tients who had at least one SIRS criterion on each day of
follow-up, and the evolution of inflammation, as defined
by trends in CRP and WCC. The criteria for SIRS inclu-
ded (1) temperature >38.3 or <36 degrees C, (2) respira-
tory rate >20 or PaCO2 < 32 mmHg, (3) heart rate >90
per minute, and (4) WCC >12 × 109/L or <4 × 109/L [1].
Because CRP and WCC had a skewed distribution, square
root and logarithmic transformations were applied to
these variables, respectively. Secondary outcomes of inter-
est were mortality and admission to HDU/ICU. Vital
status is reported as survival status either at hospital dis-
charge or at 30 day follow up.
Statistical analysis
We did not perform an a priori sample size calculation for
this single-centre pilot observational study [16]; instead,
we aimed to enrol all possible study subjects during the
period of availability of the data collectors. Continuous
data are expressed as means and standard deviations (SD)
or medians and interquartile ranges (IQR), and categorical
variables as frequencies and proportions.
Repeated measures linear regression models, which
account for within-patient correlation, were used to de-
termine associations between a priori selected predictors
(days since admission, age, gender, Charlson score, prior
statin exposure) and WCC and CRP. We used a general-
ized estimating equations model to determine asso-
ciations between the same variables and the presence of
any SIRS criteria on each day over the follow-up period.
For all models, correlation was modelled using an auto-
regressive correlation structure. For the outcome of
SIRS, we assumed that missing values represented nor-
mal values and that SIRS was present on the last day of
recorded data for any patient who died or was trans-
ferred to HDU/ICU. For WCC and CRP, we assumed
that values were missing at random. A two-sided p-value
<0.05 was taken as statistically significant. Statistical ana-
lysis was performed using SAS version 9.3 (SAS Institute
Inc., Cary, NC, USA).
Table 1 Baseline data in the study cohort
Variable Combined (n = 209) Statin (n = 58) Non-statin (n = 151) p-value1
Age (yr), mean ± SD 63.8 ± 20.7 75.4 ± 11.3 59.4 ± 21.8 <0.0001
Gender (male), n (%) 104 (49.8) 27 (46.6) 77 (51) 0.57
Charlson Index, median (IQR) 2 (1–3) 3 (2–4) 1 (0–3) <0.0001
Type of infection2
Pneumonia 106 (51.0) 27 (46.6) 79 (52.7) 0.43
Primary bacteraemia 6 (2.9) 2 (3.5) 4 (2.7) 0.68
Peritonitis/intra-abdominal 7 (3.4) 2 (3.5) 5 (3.4) 1.00
Urinary tract 70 (34.1) 23 (39.7) 47 (32.0) 0.30
Skin/soft tissue 38 (18.5) 12 (20.7) 26 (17.7) 0.69
Other3 5 (2.7) 0 (0) 5 (3.3) 0.3252
CRP (mg/L) (n = 176; 47; 129), median (IQR) 65 (17–166) 87 (32–157) 58 (16–166) 0.51
WCC (×109/L) (n = 186; 48; 138), median (IQR) 13.1 (9.1–17.7) 13.2 (9.4–17.9) 12.9 (9.0–17.6) 0.64
Lowest systolic BP (mmHg) (n = 200; 54; 146), mean ± SD 115 ± 22.1 119.4 ± 26.0 113.9 ± 20.3 0.12
Highest temperature (Celsius) (n = 201; 55; 146), mean ± SD 37.4 ± 0.99 37.4 ± 1.04 37.4 ± 0.97 0.70
Lowest temperature (Celsius) (n = 199; 54; 145), mean ± SD 36.5 ± 0.75 36.6 ± 0.80 36.4 ± 0.73 0.26
At least 1 SIRS criterion, n (%) 184 (88.0) 50 (86.2) 134 (88.7) 0.61
Lowest SaO2 < 90%, n (%) 22 (11.1) 8 (14.8) 14 (9.7) 0.30
Supplemental oxygen (n, %) 105 (50.5) 30 (51.7) 75 (50.0) 0.82
Urine output (median [IQR]), (n = 40; 12; 28) 750 (450–1237.5) 877.5 (417–1875) 750 (450–1237.5) 0.74
AVPU (n, %) (n = 191; 54; 137) 0.069
Alert 186 (97.4) 51 (94.4) 135 (98.5)
Responds to Voice 4 (2.1) 3 (5.6) 1 (0.73)
Responds to Pain 0 (0) 0 (0) 0 (0)
Unresponsive 1 (0.5) 0 (0) 1 (0.73)
Data refer to the first day of admission. Numbers in brackets, where provided, refer to the number of patients with data.
1For difference between statin versus non-statin groups.
2211 infections were identified. 4 patients did not have infection and 7 patients had >1 infection.
3Other infections included C. difficile (n = 1), osteomyelitis (n = 2), tonsillitis (n = 1), gastroenteritis (n = 1).
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Results
Description of cohort
We enrolled 209 patients over the study period (Table 1).
Patients had a mean (SD) age of 63.8 (20.7) years and
104 (49.8%) were male. The commonest infection was
pneumonia (n = 106, 51.2%), followed by urinary tract
(n = 70, 34.1%) and skin/soft tissue infections (n = 38,
18.3%). Most patients (n = 184, 88.0%) had one or more
SIRS criteria on day 1.
Fifty-eight patients (27.8%) satisfied the ‘statin user’
definition. Seven (4.6%) patients were given statin after ad-
mission in the previously no statin group and 54 (93.1%)
were administered statin in the previously statin group.
Among those receiving statin after admission, the percent-
age days of statin was 50 (33–60) in the non-statin and 90
(75–100) in the statin user group. Compared to non-statin
users, patients on statins were older (75.4 ± 11.3 versus
59.4 ± 21.8 years, p < 0.0001) and suffered more chronic
disease (Charlson score 3 [2-4] versus 1 [0–3], p < 0.0001),
but there were no statistically significant differences be-
tween groups in terms of sex, markers of inflammation, or
presence of at least 1 SIRS criteria on the first day [n = 50
(86.2%) vs. n = 134 (88.7%); p = 0.61].
Outcomes and effect of statin exposure
Sixty-four (30.6%) patients deteriorated, as reflected by an
increase in the number of positive SIRS criteria (Table 2).
Progression of illness, defined by presence of more SIRS
criteria than on study day 1, was more common in the
statin group [47.4% vs. 33.3%; p = 0.063], although the dif-
ference was not statistically significant. The progression of
illness as assessed using an increase in SIRS score over
time were not different between the statin users and non-
statin users among those whose SIRS score increased with
time [median [IQR] days 2 (2–3) vs 2 (2–3) respectively;
p = 0.57). There were no differences in evolution of other
markers of organ dysfunction beyond day 1, including
supplemental oxygen, urine output, and mental status.
Seven patients (3.3%) required admission to HDU/ICU
and twelve patients (5.7%) died within 30 days of admission.
All the deaths were in a ward setting with one of the deaths
following a readmission to hospital. The unadjusted hos-
pital LOS was shorter in the non-statin group compared to
the statin group [p = 0.013].
Overall, the proportion of patients with at least 1 SIRS
criterion decreased with time in both statin users and
non-users (Figure 1 and Table 3). When adjusted for
other variables, the number of days since admission was
significantly associated with the number of SIRS criteria
positive (OR 0.86, 95% CI 0.82–0.91, p < 0.0001). None of
age, sex, Charlson score, or statin exposure was associated
with the presence of at least 1 SIRS criterion (Table 3).
Out of 184 who had at least one SIRS criteria on day 1,
112 (60.9%) still had one SIRS on the last day of follow up.
Table 2 Outcomes in the cohort
Outcome Combined (n = 209) Statin (n = 58) Non-statin (n = 151) p-value1
Death by day 10 (n,%) 5 (2.4) 2 (3.5) 3 (2.0) 0.62
HDU/ICU admission (n,%) 7 (3.3) 2 (3.4) 5 (3.3) 1.00
HDU/ICU admission by day 10 (n,%) 8 (3.8) 3 (5.2) 5 (3.3) 0.69
Status at 30 days 0.069
Dead 12 (5.7) 3 (5.2) 9 (6.0)
In ICU/HDU 1 (0.48) 0 (0) 1 (0.66)
In ward 27 (12.9) 13 (22.4) 14 (9.3)
Discharged from hospital 169 (80.9) 42 (72.4) 127 (84.1)
More SIRS criteria at any time than recorded on day 1 (n,%) 76 (37.3) 27 (47.4) 49 (33.3) 0.063
Supplemental oxygen, days 2–10 (n,%) 96 (47.1) 30 (52.6) 66 (44.9) 0.32
Days on supplemental oxygen (median [IQR]), days 1–10 1 (0–3) 1 (0–4) 1 (0–3) 0.28
Days of antibiotics (median [IQR]), days 1–10 5 (3–8) 6.5 (4–8) 5 (3–8) 0.10
Urine output, days 2–10 (median [IQR] (n = 87; 27; 60) 1125 (725–1701.4) 1110 (691–1635) 1157.9 (732.5–1764.6) 0.42
Worst AVPU, days 2–10 (n,%) (n = 196; 54; 137) 1.00
Alert 189 (96.4) 53 (96.4) 136 (96.5)
Responds to Voice 7 (3.6) 2 (3.6) 5 (3.5)
Responds to Pain 0 0 0
Unresponsive 0 0 0
Hospital length of stay, days (median [IQR]1 8 (3–18) 10.5 (6–20) 7 (3–15) 0.013
Numbers in brackets, where provided, refer to the number of patients with data.
1 Hospital length of stay is calculated as the difference between discharge and admission date. If these dates are equal, it is counted as 1 day.
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Of twenty five patients who did not have SIRS on day 1, 13
(52%) patients had new SIRS by the last day of follow up.
CRP (Figure 2) and WCC (Figure 3) decreased over the
follow-up period. When adjusted for other variables, the
number of days since admission was again strongly
associated with lower CRP (beta coefficient -0.3237 [stand-
ard error 0.065], p < 0.0001) and lower WCC (coeffi-
cient -0.0466 [standard error 0.007], p < 0.0001). None of
age, sex, Charlson score, or statin exposure was associated
with change in CRP or WCC (Tables 4 and 5).
Discussion
Main findings
In our single-centre prospective cohort study of medical
[non-surgical] patients admitted to hospital wards for
treatment of suspected or confirmed infection, the risk
of significant clinical deterioration was low, with a 30-day
mortality of 5.7% and HDU/ICU admission risk of 3.3%.
Markers of systemic inflammation (SIRS characteristics,
CRP, WCC) improved with time. Prior statin therapy did
not alter the trajectory of these inflammatory markers. Fu-
ture larger studies may identify risk factors for progression
of illness in this population and plausible surrogate end-
points for evaluation in clinical trials.
Comparison to other work
Our main inclusion criterion, prescription of antibiotics
for suspected or proven acute infection, was designed to
identify a cohort for a future RCT of prevention of illness
progression among non-surgical hospitalised patients
with infection. This criterion was similar to the two
published RCTs of statins for sepsis [12,17]. One ran-
domized trial of simvastatin for patients with bacterial
infection, but not necessarily SIRS, found that only 4 of
83 patients progressed to severe sepsis [12]. More recently,
Figure 1 Changes in SIRS criteria over time. Percentage of patients with at least 1 SIRS criterion present on each day in statin users (black
columns) vs. non-users (grey columns). Out of 341 patient-days coded as no SIRS there are 35 days for which values are missing for all variables
in the SIRS criteria. The number of patients with data is below each column.
Table 3 Adjusted model for associations with any SIRS
criteria on any day of follow-up
Variable Odds ratio 95% Confidence
interval
P
value
Days since admission 0.86 0.82 - 0.90 <0.0001
Age (per 10 year increase) 1.06 0.96 - 1.17 0.27
Gender (male versus
female)
1.10 0.74 - 1.62 0.64
Charlson index
(per 1 unit increase)
1.05 0.97 - 1.13 0.24
Statin (versus non-statin) 1.13 0.76 - 1.69 0.55
WCC was missing on 614 (43.8%) of the 1401 patient-days of data. Using
repeated measures analysis, the amount of missing data increases over time
but does not differ between statin and non-statin groups.
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another RCT of atorvastatin for hospitalised patients
with acute infection and 2 SIRS criteria found that
14 of 100 patients progressed to severe sepsis, with a
lower risk in the atorvastatin group (p = 0.007) [17].
The presence of SIRS is likely to be associated with
the higher risk of progression of illness in the latter
RCT, and may identify a higher risk target interven-
tion group.
In our study cohort consisting of medical [non-surgical]
patients, approximately one-third of patients had progres-
sion of illness defined by an increase in number of SIRS
criteria. Compared to ward patients, the prevalence of
SIRS in a critically ill population is high. ICU-based
studies have evaluated the utility of SIRS progression
either as a risk factor for more severe illness or as a risk
factor for mortality [3,5,6,18,19]. Rangel-Frausto et al
found a higher incidence of culture-positive sepsis with in-
crease in number of SIRS criteria [3], but other studies
have found that SIRS criteria have little value in detecting
culture positive sepsis [20]. Similarly, patients with SIRS
have a mortality rate of 10% [19] and while an increase in
number of SIRS has been shown to be associated with an
increase in risk of death [20], this relationship has not
been replicated in other studies [6]. These inconsist-
ent observations suggest that SIRS criteria lack speci-
ficity and sensitivity to predict progression of illness
due to infection [2,6,19,20]. Finally, the overall mor-
tality in the study cohort was a limiting factor that
precluded modelling the influence of SIRS criteria
[2,3,5,6], CRP trends [18,21], or pneumonia [2,22] on
mortality.
Strengths and limitations
Our study provides further insights into the natural
history of bacterial infection following admission to a
medical ward. We enrolled a clearly defined and gen-
eral cohort and constructed multivariable models that
accounted for within-patient correlation to explore the ef-
fect of pre-hospital statin exposure on markers of inflam-
mation. Our study also has limitations. Many patients did
not have CRP or WCC recorded on all days, presumably
because they were clinically improving, possibly biasing
association of statin with these outcomes to the null. The
overall risk of clinically significant deterioration or death
Figure 2 Changes in C-reactive protein over the course of the study in statin users (dark grey) vs. non-users (light grey). The number of
patients with data is below each column. For each column, the dark horizontal line denotes the median value, the bottom and top of the box
denote the first and third quartiles respectively, the upper whisker extends to the highest value that is within 1.5 × interquartile range of the third
quartile, and the lower whisker extends to the lowest value within 1.5 × interquartile range of the first quartile. Data beyond the end of the
whiskers are outliers and plotted as points.
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was low, precluding multivariable analyses of associations
with these outcomes.
Future directions
Patients with sepsis syndromes are clinically heteroge-
neous, with variable illness trajectory and outcomes. The
utility of longitudinal trends in SIRS criteria and labo-
ratory trends such as CRP to predict risk of progressive
illness, ICU admission, and death must be further evalu-
ated in a larger cohort of patients. The objective of such
investigations would be to reliably identify a higher risk
group of patients in whom strategies to prevent disease
progression may be evaluated.
Conclusions
We report a cohort of hospital admissions with bacterial
infections requiring antibiotic therapy and assessed the
trajectory of changes in SIRS criteria and inflammatory
markers. The risk of clinically important adverse out-
comes in this population was low, and time since admis-
sion was the only variable associated with trends in the
number of SIRS criteria, CRP and WCC.
Figure 3 Changes in white blood cell count over the course of the study in in statin users (dark grey) vs. non-users (light grey). The
number of patients with data is below each column. For each column, the dark horizontal line denotes the median value, the bottom and top of
the box denote the first and third quartiles respectively, the upper whisker extends to the highest value that is within 1.5 × interquartile range of
the third quartile, and the lower whisker extends to the lowest value within 1.5 × interquartile range of the first quartile. Data beyond the end
of the whiskers are outliers and plotted as points.
Table 4 Adjusted model for associations with square root
of C-reactive protein
Variable Coefficient Standard error p value
Days since admission -0.3237 0.066 <0.0001
Age 0.01337 0.016 0.3970
Gender (male versus female) 1.0358 0.600 0.0850
Charlson index 0.0369 0.139 0.7903
Statin (versus non-statin) 0.1063 0.693 0.8781
C-reactive protein was missing on 682 (48.7%) of the 1401 patient-days of
data. Using repeated measures analysis, the amount of missing data increases
over time but does not differ between statin and non-statin groups.
Table 5 Adjusted model for associations with logarithm
of white cell count
Variable Coefficient Standard error P value
Time -0.0469 0.007 <0.0001
Age 0.0006 0.0015 0.6806
Gender (male versus female) 0.0599 0.057 0.2940
Charlson index -0.0219 0.013 0.0952
Statin (versus non-statin) 0.037 0.066 0.5731
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